Norditropin Flexpro (Somatropin)

Somatropin, the active ingredient in Norditropin FlexPro, is a growth hormone presented as a 5 mg per pen (3.33 mg/mL) injectable solution for subcutaneous use. It treats growth hormone deficiency and related growth disorders in children and adults, and is indicated for several endocrine conditions that affect linear growth.

GNH USA supplies Norditropin FlexPro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable cold‑chain logistics and regulatory support with a focus on quality assurance and timely delivery to meet clinical demand.

Norditropin FlexPro (somatropin) is used in endocrine therapy to address growth hormone deficiency and related conditions. - Growth hormone deficiency in children: promotes linear growth and improves height velocity. - Turner syndrome: supports growth and development during puberty. - Prader‑Willi syndrome: enhances growth and body composition. - Chronic renal insufficiency associated growth failure: aids in achieving normal growth patterns. - Short stature due to idiopathic causes: stimulates growth in otherwise healthy children. - Adult growth hormone deficiency: improves body composition, bone density and quality of life.

Somatropin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Headache: mild to moderate intensity. - Joint stiffness: transient discomfort in joints. - Edema: mild fluid retention, especially in extremities. - Hyperglycemia: elevated blood glucose levels, often mild.

Serious or Rare Side Effects: - Intracranial hypertension: signs include severe headache, visual changes, nausea. - Slipped capital femoral epiphysis: hip pain and limited motion. - Acute pancreatitis: abdominal pain, nausea, elevated enzymes. - Allergic reactions: rash, urticaria, anaphylaxis. - Neoplasia progression: potential acceleration of existing tumors.

Before initiating therapy, clinicians should consider several safety measures. - Screening: assess baseline IGF‑1 and glucose levels before initiating therapy. - Monitoring: regularly evaluate growth response, IGF‑1, and metabolic parameters. - Diabetes risk: monitor for hyperglycemia, especially in patients with pre‑existing diabetes. - Intracranial pressure: watch for persistent headaches, visual disturbances. - Cancer history: avoid or use with caution in patients with active malignancies. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Glucocorticoids: may antagonize growth‑promoting effects. - Antidiabetic agents: somatropin can reduce glycemic control, requiring dose adjustment. - Estrogen therapy: high doses may interfere with IGF‑1 response.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: monitor thyroid function as GH can increase conversion. - Oral contraceptives: may alter IGF‑1 levels, requiring periodic assessment. - Insulin: may need dose titration due to altered glucose metabolism.